We are live on ! Find out more
HBIO icon

Harvard Bioscience
HBIO

Fund managers haven’t disclosed any holdings of HBIO yet.

HBIO Hedge Fund Activity: Q1 2026 in Review

36 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2026, worth a combined $7.72M — down 34% from $11.7M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of HBIO and 3 opened new positions — a net loss of 26 holders — while 17 trimmed existing stakes and 10 added.

The largest buyer was Nano-Cap New Millennium Growth Fund, adding an estimated $321K. The largest seller was Portolan Capital Management, exiting entirely with an estimated $274K sold.

  • 36 institutional investors held Harvard Bioscience (HBIO) as of Q1 2026, down from 63 in Q4 2025.
  • Funds reported $7.72M of Harvard Bioscience stock for Q1 2026, down 34% quarter-over-quarter.
  • 3 funds opened new Harvard Bioscience positions in Q1 2026 and 29 closed out, a net change of -26 holders.
  • The largest Harvard Bioscience buyer in Q1 2026 was Nano-Cap New Millennium Growth Fund, an estimated $321K added.
  • The largest Harvard Bioscience seller in Q1 2026 was Portolan Capital Management, an estimated $274K sold.

Based on aggregated 13F filings for Q1 2026.